PT - JOURNAL ARTICLE AU - Bhalala, Oneil G. AU - Beamish, Jessica AU - Eratne, Dhamidhu AU - Summerell, Patrick AU - Porter, Tenielle AU - Laws, Simon M. AU - Kang, Matthew JY AU - Huq, Aamira J. AU - Chiu, Wei-Hsuan AU - Cadwallader, Claire AU - Walterfang, Mark AU - Farrand, Sarah AU - Evans, Andrew H. AU - Kelso, Wendy AU - Churilov, Leonid AU - Watson, Rosie AU - Yassi, Nawaf AU - Velakoulis, Dennis AU - Loi, Samantha M. TI - Blood biomarker profiles in young-onset neurocognitive disorders: a cohort study AID - 10.1101/2024.06.30.24309746 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.30.24309746 4099 - http://medrxiv.org/content/early/2024/07/01/2024.06.30.24309746.short 4100 - http://medrxiv.org/content/early/2024/07/01/2024.06.30.24309746.full AB - INTRODUCTION This study investigates the blood biomarkers associated with young-onset neurocognitive disorders.METHODS Sixty-five participants less than 65 years old with neurocognitive symptoms (median age at assessment of 58 years, 42% female) were categorised as either early-onset Alzheimer’s disease (EOAD, n=18), non-AD neurodegeneration (nAD-ND, n=23) or primary psychiatric disorders (PPD, n=24). Levels of neurofilament light chain, glial fibrillary acidic protein and phosphorylated-tau 181, apolipoprotein E genotype and late-onset AD polygenic risk scores were determined. Information-theoretic model selection identified discriminatory factors.RESULTS: Glial fibrillary acidic protein was up to 3.5-fold higher in individuals with EOAD compared to other diagnostic categories. A combination of cognitive and blood biomarkers, but not the polygenic risk score, discriminated between diagnostic categories. Phosphorylated-tau 181 alone significantly discriminated between EOAD and nAD-ND causes.DISCUSSION Discriminating between EOAD, nAD-ND and PPD causes of young-onset neurocognitive symptoms is possible by combining cognitive profiles with blood biomarkers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementOGB was supported by the Melbourne Genomics Health Alliance Genomics Immersion Fellowship. Funders did not have a role in the generation or analysis of the data or in the development of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by the Royal Melbourne Hospital/Melbourne Health Human Research Ethics Committee (MH 2018.371).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.